Robert W. Watkins

1.1k total citations
37 papers, 795 citations indexed

About

Robert W. Watkins is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Robert W. Watkins has authored 37 papers receiving a total of 795 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 9 papers in Molecular Biology and 6 papers in Surgery. Recurrent topics in Robert W. Watkins's work include Nitric Oxide and Endothelin Effects (4 papers), Neuropeptides and Animal Physiology (4 papers) and Receptor Mechanisms and Signaling (4 papers). Robert W. Watkins is often cited by papers focused on Nitric Oxide and Endothelin Effects (4 papers), Neuropeptides and Animal Physiology (4 papers) and Receptor Mechanisms and Signaling (4 papers). Robert W. Watkins collaborates with scholars based in United States, United Kingdom and China. Robert W. Watkins's co-authors include Channing R. Robertson, Edmund J. Sybertz, Harry R. Davis, Subbarao Vemulapalli, Thomas Baum, Kevin B. Alton, Robert E. Burrier, Ho Sam Ahn, Ho-Sam Ahn and Nicholas Prioli and has published in prestigious journals such as Journal of Medicinal Chemistry, The American Journal of Cardiology and International Journal of Heat and Mass Transfer.

In The Last Decade

Robert W. Watkins

36 papers receiving 713 citations

Peers

Robert W. Watkins
Yuefei Shen United States
Dahai Wang China
José A. Cisneros United States
Ádám Kemény‐Beke Hungary
Zhiping Jiang China
Li Hua China
Thomas Seidel Germany
Eric C. Peterson United States
Richard Isaacs United Kingdom
Stephen J. Everse United States
Yuefei Shen United States
Robert W. Watkins
Citations per year, relative to Robert W. Watkins Robert W. Watkins (= 1×) peers Yuefei Shen

Countries citing papers authored by Robert W. Watkins

Since Specialization
Citations

This map shows the geographic impact of Robert W. Watkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert W. Watkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert W. Watkins more than expected).

Fields of papers citing papers by Robert W. Watkins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert W. Watkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert W. Watkins. The network helps show where Robert W. Watkins may publish in the future.

Co-authorship network of co-authors of Robert W. Watkins

This figure shows the co-authorship network connecting the top 25 collaborators of Robert W. Watkins. A scholar is included among the top collaborators of Robert W. Watkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert W. Watkins. Robert W. Watkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Watkins, Robert W., et al.. (2021). Data-Driven Dose-Volume Histogram Prediction. Advances in Radiation Oncology. 7(2). 100841–100841. 3 indexed citations
2.
Watkins, Robert W., et al.. (2009). Packaging and Transportation of Neptunium Oxide. 97–99.
3.
Carey, Galen, William Billard, Herbert Binch, et al.. (2001). SCH 57790, a selective muscarinic M2 receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals. European Journal of Pharmacology. 431(2). 189–200. 59 indexed citations
4.
5.
Chintala, Madhu, et al.. (1998). Disparate effects of thrombin receptor activating peptide on platelets and peripheral vasculature in rats. European Journal of Pharmacology. 349(2-3). 237–243. 9 indexed citations
6.
Xia, Yan, Samuel Chackalamannil, Michael Czarniecki, et al.. (1997). Synthesis and Evaluation of Polycyclic Pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP Phosphodiesterase Inhibitors. Journal of Medicinal Chemistry. 40(26). 4372–4377. 39 indexed citations
7.
Vemulapalli, Subbarao, Robert W. Watkins, Madhu Chintala, et al.. (1996). Antiplatelet and Antiproliferative Effects of SCH 51866, a Novel Type 1 and Type 5 Phosphodiesterase Inhibitor. Journal of Cardiovascular Pharmacology. 28(6). 862–869. 45 indexed citations
8.
Neustadt, Bernard R., Elizabeth M. Smith, Terry L. Nechuta, et al.. (1994). Mercaptoacyl aminoacid inhibitors of atriopeptidase. 1. Structure-activity relationship studies of methionine and S-alkylcysteine derivatives. Journal of Medicinal Chemistry. 37(15). 2461–2476. 10 indexed citations
9.
Sybertz, Edmund J., Peter J.S. Chiu, Robert W. Watkins, & Subbarao Vemulapalli. (1991). Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action. Canadian Journal of Physiology and Pharmacology. 69(10). 1628–1635. 13 indexed citations
10.
Sybertz, Edmund J. & Robert W. Watkins. (1989). Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective beta2 agonist-mediated vasodilation and beta antagonism. The American Journal of Cardiology. 63(19). I3–I6. 7 indexed citations
11.
Watkins, Robert W., et al.. (1988). Systemic Effects Resulting from Topical Ocular Administration of SCH 33861, a Novel ACE Inhibitor Ocular Hypotensive Agent. Journal of Ocular Pharmacology and Therapeutics. 4(2). 93–100. 10 indexed citations
12.
Watkins, Robert W., et al.. (1988). Effects of the Antihypertensive Dilevalol on Aortic Compliance in Anesthetized Dogs. Journal of Cardiovascular Pharmacology. 12(1). 42–50. 7 indexed citations
13.
Watkins, Robert W., et al.. (1987). Topical Ocular Hypotensive Effects of the Novel Angiotensin Converting Enzyme Inhibitor SCH 33861 in Conscious Rabbits. Journal of Ocular Pharmacology and Therapeutics. 3(4). 295–307. 42 indexed citations
14.
Watkins, Robert W., et al.. (1987). Nitroprusside, but not ANF inhibits venoconstriction in an in situ rat model. European Journal of Pharmacology. 143(3). 299–304. 1 indexed citations
15.
Sybertz, Edmund J., Robert W. Watkins, Ho Sam Ahn, et al.. (1987). Pharmacologic, Metabolic, and Toxicologic Profile of Spirapril (SCH 33844), a New Angiotensin Converting Inhibitor. Journal of Cardiovascular Pharmacology. 10. 105–108. 15 indexed citations
16.
Watkins, Robert W., et al.. (1987). Effects of the Antihypertensive Dilevalol on Large Artery Compliance in Anesthetized Dogs. Journal of Cardiovascular Pharmacology. 10. S58–S63. 8 indexed citations
17.
Watkins, Robert W., et al.. (1985). Comparative Effects of SCH 19927 and Timolol on Intraocular Pressure of Conscious Rabbits and Relative Systemic Beta-blockade Resulting from Topical Administration. Journal of Ocular Pharmacology and Therapeutics. 1(2). 161–168. 3 indexed citations
18.
Smith, Sharon P., et al.. (1985). Retrospective Conversion of Serials at the University of Houston:. The Serials Librarian. 9(3). 63–68. 1 indexed citations
19.
20.
Watkins, Robert W., Channing R. Robertson, & Andreas Acrivos. (1976). Entrance region heat transfer in flowing suspensions. International Journal of Heat and Mass Transfer. 19(6). 693–695. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuefei Shen Breakdown of academic impact, for papers by Dahai Wang Breakdown of academic impact, for papers by José A. Cisneros Breakdown of academic impact, for papers by Ádám Kemény‐Beke Breakdown of academic impact, for papers by Zhiping Jiang Breakdown of academic impact, for papers by Li Hua Breakdown of academic impact, for papers by Thomas Seidel Breakdown of academic impact, for papers by Eric C. Peterson Breakdown of academic impact, for papers by Richard Isaacs Breakdown of academic impact, for papers by Stephen J. Everse
Rankless by CCL
2026